Select Page

News

Application to FDA for lonafarnib approval is COMPLETE!

Application to FDA for lonafarnib approval is COMPLETE!

During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval – in Europe and the US – of the drug lonafarnib as a first-ever treatment for Progeria.

read more
Submission of application to FDA for lonafarnib approval has begun!

Submission of application to FDA for lonafarnib approval has begun!

We’re thrilled to announce a milestone in our mission to treat and cure children with Progeria: In partnership with The Progeria Research Foundation, Eiger BioPharmaceuticals has submitted to the FDA the first part of its application seeking approval of the drug lonafarnib as a treatment for Progeria.

read more
PRF’s 2019 Newsletter

PRF’s 2019 Newsletter

Get exciting updates on our progress over the past year, learn why we now refer to the population we serve as children – and young adults – with Progeria, check out the people, the science, and the events that got us where we are today, and SO MUCH MORE!

read more
‘Find the Children’ campaign launches in India

‘Find the Children’ campaign launches in India

Due to the incredible success of previous years’ campaigns in 2009 and 2015, we are thrilled to announce the 2019 launch our ‘Find the Children’ initiative to search globally for the undiagnosed children with Progeria so that they, too, can have access to the unique care they need.

read more